Impact of CDK4/6 Inhibitors on Health-Related Quality of Life Outcomes in Patients With Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
November 2025
in “
Journal of Managed Care & Specialty Pharmacy
”
Studysummary This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on doi.org →